The pathophysiology and treatment of hereditary tyrosinemia type 1

Research output: Contribution to journalArticle

114 Citations (Scopus)

Abstract

The topic of this review is hepatorenal tyrosinemia (hereditary tyrosinemia type 1 [HT1], or fumarylacetoacetate hydrolase deficiency; OMIM# 276700). HT1 is the most serious and common of the genetic defects in tyrosine degradation. In addition, this disorder has importance as a model of spontaneous self-correction of liver disease, as a model of liver repopulation by transplanted cells and gene therapy, and as a genetic cause of hepatocarcinoma. However, other forms of hypertyrosinemia exist; hence, the differential diagnosis also will be described briefly. Recent years have seen much progress in our understanding of the molecular basis, the pathophysiology, and especially the treatment of HT1. The current intervention with 2-(2-nitro-4-trifluoro-methylbenzyol)-1,3 cyclohexanedione (NTBC) therapy has improved the outcome of this once devastating disorder. The successful repopulation of the HT1 liver with transplanted cells and positive results in the use of gene therapy in animal models may someday lead to therapy in humans that will obviate the need for life-long dietary and pharmacological therapy.

Original languageEnglish (US)
Pages (from-to)563-571
Number of pages9
JournalSeminars in Liver Disease
Volume21
Issue number4
DOIs
StatePublished - 2001

Fingerprint

Tyrosinemias
Genetic Therapy
Therapeutics
Genetic Databases
Liver
Cell- and Tissue-Based Therapy
Tyrosine
Liver Diseases
Differential Diagnosis
Animal Models
Pharmacology

Keywords

  • Hepatocarcinoma therapy
  • Succinylacetone
  • Tyrosinemia

ASJC Scopus subject areas

  • Hepatology

Cite this

The pathophysiology and treatment of hereditary tyrosinemia type 1. / Grompe, Markus.

In: Seminars in Liver Disease, Vol. 21, No. 4, 2001, p. 563-571.

Research output: Contribution to journalArticle

@article{57d3318ee99a47ac833f9b785a7edcf4,
title = "The pathophysiology and treatment of hereditary tyrosinemia type 1",
abstract = "The topic of this review is hepatorenal tyrosinemia (hereditary tyrosinemia type 1 [HT1], or fumarylacetoacetate hydrolase deficiency; OMIM# 276700). HT1 is the most serious and common of the genetic defects in tyrosine degradation. In addition, this disorder has importance as a model of spontaneous self-correction of liver disease, as a model of liver repopulation by transplanted cells and gene therapy, and as a genetic cause of hepatocarcinoma. However, other forms of hypertyrosinemia exist; hence, the differential diagnosis also will be described briefly. Recent years have seen much progress in our understanding of the molecular basis, the pathophysiology, and especially the treatment of HT1. The current intervention with 2-(2-nitro-4-trifluoro-methylbenzyol)-1,3 cyclohexanedione (NTBC) therapy has improved the outcome of this once devastating disorder. The successful repopulation of the HT1 liver with transplanted cells and positive results in the use of gene therapy in animal models may someday lead to therapy in humans that will obviate the need for life-long dietary and pharmacological therapy.",
keywords = "Hepatocarcinoma therapy, Succinylacetone, Tyrosinemia",
author = "Markus Grompe",
year = "2001",
doi = "10.1055/s-2001-19035",
language = "English (US)",
volume = "21",
pages = "563--571",
journal = "Seminars in Liver Disease",
issn = "0272-8087",
publisher = "Thieme Medical Publishers",
number = "4",

}

TY - JOUR

T1 - The pathophysiology and treatment of hereditary tyrosinemia type 1

AU - Grompe, Markus

PY - 2001

Y1 - 2001

N2 - The topic of this review is hepatorenal tyrosinemia (hereditary tyrosinemia type 1 [HT1], or fumarylacetoacetate hydrolase deficiency; OMIM# 276700). HT1 is the most serious and common of the genetic defects in tyrosine degradation. In addition, this disorder has importance as a model of spontaneous self-correction of liver disease, as a model of liver repopulation by transplanted cells and gene therapy, and as a genetic cause of hepatocarcinoma. However, other forms of hypertyrosinemia exist; hence, the differential diagnosis also will be described briefly. Recent years have seen much progress in our understanding of the molecular basis, the pathophysiology, and especially the treatment of HT1. The current intervention with 2-(2-nitro-4-trifluoro-methylbenzyol)-1,3 cyclohexanedione (NTBC) therapy has improved the outcome of this once devastating disorder. The successful repopulation of the HT1 liver with transplanted cells and positive results in the use of gene therapy in animal models may someday lead to therapy in humans that will obviate the need for life-long dietary and pharmacological therapy.

AB - The topic of this review is hepatorenal tyrosinemia (hereditary tyrosinemia type 1 [HT1], or fumarylacetoacetate hydrolase deficiency; OMIM# 276700). HT1 is the most serious and common of the genetic defects in tyrosine degradation. In addition, this disorder has importance as a model of spontaneous self-correction of liver disease, as a model of liver repopulation by transplanted cells and gene therapy, and as a genetic cause of hepatocarcinoma. However, other forms of hypertyrosinemia exist; hence, the differential diagnosis also will be described briefly. Recent years have seen much progress in our understanding of the molecular basis, the pathophysiology, and especially the treatment of HT1. The current intervention with 2-(2-nitro-4-trifluoro-methylbenzyol)-1,3 cyclohexanedione (NTBC) therapy has improved the outcome of this once devastating disorder. The successful repopulation of the HT1 liver with transplanted cells and positive results in the use of gene therapy in animal models may someday lead to therapy in humans that will obviate the need for life-long dietary and pharmacological therapy.

KW - Hepatocarcinoma therapy

KW - Succinylacetone

KW - Tyrosinemia

UR - http://www.scopus.com/inward/record.url?scp=0035196687&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035196687&partnerID=8YFLogxK

U2 - 10.1055/s-2001-19035

DO - 10.1055/s-2001-19035

M3 - Article

C2 - 11745044

AN - SCOPUS:0035196687

VL - 21

SP - 563

EP - 571

JO - Seminars in Liver Disease

JF - Seminars in Liver Disease

SN - 0272-8087

IS - 4

ER -